Docket No. 55-310P

Part.

10. Antibodies according to claim 9, wherein said antibodies are monoclonal antibodies.--

The specification has been amended to recite "and polyclonal." Support for polyclonal antibodies may be found in working Examiner 3(c) in that the antibodies produced in the mouse and the isolated antibody producing spleenocytes are polyclonal in nature. In addition, the hybridoma cultures of Working Example 3(e) produce polyclonal antibodies.

REMARKS

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Applicants' further respectfully request that the disk containing the amended sequence listing which was filed in parent application No. 08/448,489 on February 26, 1999 as file name "55-290p.app" be transferred to this new application in compliance with 37 C.F.R.§ 1.821-825. The disk copy of the sequence listing is identical to the paper copy except for word processing formatting.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact MaryAnne Armstrong, Ph.D. (Reg. 40,069) at the telephone number of the undersigned below.

Docket No. 55-310P

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,
BIRCH, STEWART, KOLASCH & BIRCH, LLP

By mary and Cumston (19 No400 (49)
Warc S. Weiner, #32, 181

MSW/MAA/csp 55-310P P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

(Rev. 04/19/2000)